Concord Biotech Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Concord Biotech Limited generated cash of $2,654,671,000, which is more than the previous year. Cash used in financing activities reached the amount of -$992,149,000 last year. Net change in cash is therefore $116,429,000.
Cash Flow
| 2020 | 1.54B | -1.12B | -434.16M |
|---|---|---|---|
| 2023 | 2.46B | -1.57B | -852.19M |
| 2024 | 2.65B | -1.54B | -992.14M |
CONCORDBIO.NS Cash Flow Statement (2019 – 2023)
| 2023 | 2022 | 2019 | |
|---|---|---|---|
Cash at beginning of period | 34.99M | 6.66M | 37.59M |
Operating activities | |||
Net income | 3.08B | 3.22B | 1.69B |
| Adjustments to reconcile net income to cash generated by operating activities: | |||
Depreciation and amortization | 535.91M | 540.32M | 210.88M |
Stock-based compensation expense | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||
Accounts receivable, net | -786.59M | -430.97M | -294.31M |
Inventories | 43.60M | -172.27M | -195.14M |
Accounts payable | -112.86M | 0 | 0 |
Cash generated by operating activities | 2.65B | 2.46B | 1.54B |
Investing activities | |||
Purchases Of Investments | -8.38B | -6.43B | 0 |
Investments In Property Plant And Equipment | -856.88M | -1.45B | -1.55B |
Acquisitions Net | 0 | 0 | 0 |
Cash generated by investing activities | -1.54B | -1.57B | -1.12B |
Financing activities | |||
Common Stock Issued | 0 | 0 | 0 |
Payments for dividends | -714.52M | -535.63M | -805.45M |
Repurchases of common stock | 0 | 0 | 0 |
Repayments of term debt | -265.03M | -265.96M | 374.2M |
Cash used in financing activities | -992.14M | -852.19M | -434.16M |
Net Change In Cash | 116.42M | 28.32M | -13.51M |
Cash at end of period | 151.42M | 34.99M | 24.08M |
| Data source | Data source | Data source |